

(43) International Publication Date
6 August 2015 (06.08.2015)(10) International Publication Number
WO 2015/116786 A1

(51) International Patent Classification:

C07D 405/14 (2006.01) **C07D 237/14** (2006.01)
C07D 309/40 (2006.01) **C07D 239/34** (2006.01)
C07C 271/22 (2006.01) **C07D 405/12** (2006.01)
C07D 319/06 (2006.01) **C07C 229/34** (2006.01)
C07D 231/14 (2006.01) **C07D 249/10** (2006.01)
C07D 231/18 (2006.01) **C07D 249/12** (2006.01)
C07D 231/20 (2006.01) **C07D 249/18** (2006.01)
C07D 233/70 (2006.01) **C07D 471/04** (2006.01)
C07D 233/90 (2006.01) **C07D 261/12** (2006.01)
C07D 401/04 (2006.01) **C07D 263/18** (2006.01)
C07D 235/08 (2006.01) **C07D 295/10** (2006.01)
C07D 403/06 (2006.01)

(21) International Application Number:

PCT/US2015/013459

(22) International Filing Date:

29 January 2015 (29.01.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/933,406 30 January 2014 (30.01.2014) US
 62/016,742 25 June 2014 (25.06.2014) US

(71) **Applicant** (for all designated States except US):
THERAVANCE BIOPHARMA R&D IP, LLC
 [US/US]; 901 Gateway Boulevard, South San Francisco,
 California 94080 (US).

(72) **Inventors:** **FLEURY, Melissa**; 1023 Divisadero Street,
 San Francisco, California 94115 (US). **BEAUSOLIEL,**
Anne-Marie; 1210 S. Claremont Street, San Mateo, Cali-

fornia 94402 (US). **HUGHES, Adam D.**; 1221 Judson
 Street, Belmont, California 94002 (US). **LONG, Daniel**
D.; 10 Sunview Drive, San Francisco, California 94131
 (US). **WILTON, Donna A.A.**; 181 Fair Oaks Street, San
 Francisco, California 94110 (US).

(74) **Agents:** **HAGENA, Jeffrey, A.** et al.; Theravance Bio-
 pharma US, Inc., 901 Gateway Boulevard, South San Fran-
 cisco, California 94080 (US).

(81) **Designated States** (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: NEPRILYSIN INHIBITORS



(57) **Abstract:** In one aspect, the invention relates to compounds having the formula (I): where R¹-R⁶ are as defined in the specifica-
 tion, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the inven-
 tion relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and in-
 termediates for preparing these compounds.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*